James Lock's research focused on improving procedures to correct congenital heart defects in infants and children. He has developed and provided the initial descriptions of nearly a dozen new techniques in interventional cardiology
Dr. Lock was one of the inventors of the CardioSEAL� device, which is implanted through a catheter to correct certain congenital heart defects. CardioSEAL is FDA-approved under Humanitarian Use Guidelines for the treatment of ventricular septal defect, Fontan fenestration, and patent foramen ovale, and for treating atrial septal defect in clinical trials. STARflex, a second-generation device, is being tested in clinical trials for the same indications.
About James Lock
James Lock received his MD from Stanford University School of Medicine. He completed an internship and residency at the University of Minnesota Hospital & Clinics and a fellowship at the Hospital for Sick Children in Toronto.
- Kreutzer J, Ryan CA, Wright JA Jr, Jenkins KJ, Marx G, Van Praagh R, Lock JE. Acute animal studies of the STARFlex system: a new self-centering cardioSEAL septal occluder. Catheterization & Cardiovascular Interventions 2002; 49: 225-233.
- Goff DA, Blume ED, Gauvreau K, Mayer JE, Lock JE, Jenkins KJ. Clinical outcome of fenestrated Fontan patients after closure: the first 10 years. Circulation 2002; 102: 2094-2099.
- Hung J, Landzberg MJ, Jenkins KJ, King ME, Lock JE, Palacios IF, Lang P. Closure of patent foramen ovale for paradoxical emboli: intermediate-term risk of recurrent neurological events following transcatheter device placement. Journal of the American College of Cardiology 2000; 35: 1311-1316.